about
Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression managementCurrent status of immunosuppression in liver transplantationPosttransplant metabolic syndrome in the withdrawal of immunosuppression in Pediatric Liver Transplant Recipients (WISP-R) pilot trialCystic fibrosis related liver disease--another black box in hepatology.NAFLD and liver transplantation: Current burden and expected challenges.Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular eventsMetabolic syndrome after a liver transplantation in an Asian population.Lactobacillus plantarum NCU116 attenuates cyclophosphamide-induced intestinal mucosal injury, metabolism and intestinal microbiota disorders in mice.Metabolic Syndrome Components After Pediatric Liver Transplantation: Prevalence and the Impact of Obesity and ImmunosuppressionThe Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence.Cardiovascular risk, atherosclerosis and metabolic syndrome after liver transplantation: a mini review.The multiple universes of estrogen-related receptor α and γ in metabolic control and related diseases.Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study.Sarcopenic obesity with metabolic syndrome: a newly recognized entity following living donor liver transplantation.Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases.Cerebrovascular events in 20 years of follow-up after liver transplantation: an underestimated issue?Cardiovascular risk and events after liver transplantation. Experiences from 313 consecutive transplants with a follow-up of 20 years.
P2860
Q26772295-222D63A4-792E-4BAF-8273-B7FAF960CCADQ27694591-3FD85A01-2155-4075-A249-2975E7B96FC6Q28647771-FCBF5E92-8D1E-4F96-9453-8C04288EEBE3Q28655881-45E6901B-BB2E-45F5-9B7B-7FFCBFA5F2B9Q30248646-3A1BFA69-5728-45B2-9A46-B26112DCD233Q33812634-2EBBE850-A4BF-4C5B-B23E-F954F8B468D5Q35924990-8BA84FDD-8D42-4F4F-8906-6D1952C0CAF1Q35932477-77410830-0284-4EF2-9F41-D92978B03795Q36922389-133DCF57-A33B-4ECE-8DA2-46799355CC39Q37639714-F4806354-4D1C-4626-A0B3-C36DB30CF351Q38103630-93D2486D-36B4-48D2-9D49-3CF0424F23C8Q38286999-333AD15B-8B0F-40AE-81A6-BAFCD3D2BD8CQ40132359-F5512861-9E22-41D1-A9D4-7D3C998C1ABCQ41573795-11C2123F-2C9A-439D-A978-44EFB396E756Q46957206-2A128550-DA8E-4FDB-BA7C-490E2F3CC91EQ52849522-75FBC010-5047-4898-A258-914AE5C85551Q53633173-D57A4275-4873-400A-A968-3B8E873328E3
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Metabolic syndrome: is immunosuppression to blame?
@en
Metabolic syndrome: is immunosuppression to blame?
@nl
type
label
Metabolic syndrome: is immunosuppression to blame?
@en
Metabolic syndrome: is immunosuppression to blame?
@nl
prefLabel
Metabolic syndrome: is immunosuppression to blame?
@en
Metabolic syndrome: is immunosuppression to blame?
@nl
P2860
P356
P1476
Metabolic syndrome: is immunosuppression to blame?
@en
P2093
Kymberly D Watt
P2860
P304
P356
10.1002/LT.22386
P478
17 Suppl 3
P577
2011-11-01T00:00:00Z